Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1

31 Jan 2023

Abstract excerpt

Selinexor (KPT-330), a small-molecule inhibitor of exportin-1 (XPO1, CRM1) with potent anticancer activity, has recently been granted FDA approval for treatment of relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL), with a number of additional indications currently under clinical investigation. Since selinexor has often demonstrated synergy when used in combination with other drugs,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Nuclear Structure and Function
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36731340
DOI: 10.1016/j.biopha.2023.114305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1PMID 36731340Read ↗

A three gene signature predicts response to selinexor in multiple myelomaSemantic proximity Read ↗

Combining selinexor with alisertib to target the p53 pathway in neuroblastomaSemantic proximity Read ↗

Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.Semantic proximity Read ↗

Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition.Semantic proximity Read ↗

Protein biomarkers for response to XPO1 inhibition in haematologic malignanciesSemantic proximity Read ↗

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.Semantic proximity Read ↗

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myelomaSemantic proximity Read ↗

Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.Semantic proximity Read ↗

Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its InhibitorSemantic proximity Read ↗

A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphomaSemantic proximity Read ↗

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myelomaSemantic proximity Read ↗

The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.